Collectively, these observations indicate FOXP1 is oncogenic, and that epigenetic regulation of the FOXP1 promoter is one mechanism by which PRMT5 drives BCSC function, promoting tumour initiation and drug resistance (Fig. 1). Here, FOXP1 is linked to neoplasm.